MedTrace Logo

AZD6088 Single Ascending Dose Study

NCT00931541 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2009-09-10

No results posted yet for this study

Summary

The aims of the study are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD6088 following single ascending dose administration in healthy male and non-fertile females.

Conditions

  • Healthy Volunteers

Interventions

DRUG

AZD6088

Oral solution. Each subject will receive a single-dose of AZD6088.

DRUG

Placebo

Oral solution. Each subject will receive a single-dose of placebo.

Sponsors & Collaborators

Principal Investigators

  • Biljana Lilja · AstraZeneca R&D, Södertälje, Sweden

  • Marianne Kasti · Quintiles GDRU, London, UK

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Completion
2009-08-31

Countries

  • United Kingdom

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00931541 on ClinicalTrials.gov